Ghent / Madrid — MyCartis today announced the launch of Evalution™,

a multiplex biomarker analysis platform for the life sciences research market.

Evalution™ is MyCartis’ digital multiplex analysis platform tailored to clinical research and

pharmaceutical markets and designed to analyze a broad range of protein and nucleic

acid-based biomarkers, delivering high quality data and rapid results. Evalution™ provides

an integrated reaction and detection environment and simultaneous analysis of large

numbers of analytes per assay.

Biocartis’ Swiss business unit Evalution™ and Belgian-based Pronota NV have recently joined

forces in MyCartis NV. The combination of the Evalution™ platform as designed by Biocartis,

and Pronota’s portfolio of validated biomarkers will deliver state-of-the-art solutions for a

range of diseases in the fields of cardiovascular and women’s health.

“We believe that every individual has the right to good health. But we know that the current

health model of ‘one size fits all’ is unsustainable”, said Paul Ladestein, CEO of MyCartis.

“By developing biomarker analysis solutions at the forefront of innovation we want to improve

healthcare worldwide. Our next generation multiplexing platform Evalution™ will support

researchers to better understand the role of biomarkers in early disease and risk diagnosis and

patient management. Evalution™ can analyse an individual’s protein and molecular profile in

a single assay plate”.

Besides serving the research community, MyCartis also engages in licensing opportunities with

companies aiming to develop their own commercial applications on the Evalution™ platform.

Furthermore, MyCartis also develops and validates novel applications with simpler assay formats

and unique biomarkers for a range of diseases.

The launch of Evalution™ was announced at the HUPO event in Madrid. MyCartis also launches

a new brand identity, including a new website and a blog, in which key

opinion leaders and experts in biomarker research and personalized

healthcare are interviewed.

About MyCartis

MyCartis originates from the business combination of Biocartis’ business unit Evalution™

and Pronota NV. MyCartis has a seasoned team of 50 employees and is located in

Lausanne (Switzerland) and Ghent (Belgium). MyCartis regroups all the competencies

for development and commercialization of novel biomarker assays and system

engineering to deliver unique solution for the life science industry. Operating at the

forefront of technology, it is MyCartis’ ambition to enable basic and clinical researchers

to accelerate biomarker testing through its next generation multiplex biomarker analysis

platform. The Evalution™ platform and its applications provide academic centres,

laboratories and pharmaceutical companies with an unprecedented level of biomarker

information very quickly, accurately and cost-effectively. The real benefit and practical

implementation of personalized medicine can only be achieved through a thorough

understanding and clinical validation of the constantly growing number of biomarkers.

Together with its partners that share the company’s vision, MyCartis has the objective

to accelerate innovation in healthcare and help to implement a more molecular- driven

medicine that requires high performance molecular testing platforms.

www.mycartis.net

The Evalution™ platform is currently intended for research only.

Not for use in diagnostics procedures.